Lee Karras
Group Chief ExecutiveMr. Karras joined Noramco in April, 2020, as Group Chief Executive. Prior to that he was a Director at SK Capital providing operational, sales and general management guidance to SK Capital portfolio companies in the healthcare sector.
Most recently, Mr. Karras served as CEO of Halo Pharmaceuticals Inc, an SK Capital Partners portfolio company that was sold to Cambrex Corp in 2018. Prior to Halo, he was President of IBA Molecular North America (also an SK Capital Partners portfolio company) that was sold to Illinois Health and Sciences in 2015. Prior to IBA, Mr. Karras was President and CEO of AAIPharma Services Company where he led the company’s transition from bankruptcy to a successful exit in 2009. Prior to AAI, Lee held various positions at Baxter Healthcare and Cook Medical (Cook and Baxter Pharmaceutical Solutions) where he served as General Manager and helped build the pharmaceutical services start up into a sizable sterile injectable pharma services business.
Lee holds a bachelor’s degree in chemistry from Indiana University Bloomington and a Masters of Science in Environmental Science from Indiana University Bloomington School of Public and Environmental Affairs.
Alan Majewski
President and Chief Financial OfficerAlan manages the day-to-day and long-term operational and financial responsibilities for Noramco. Before joining the company in September of 2017, Alan served as the Executive Vice President of Nippon Steel and Sumitomo Metal Corporation’s Standard Steel subsidiary, where he held broad operational and financial responsibilities. He previously served as Standard Steel’s Chief Financial Officer, where he successfully guided the Company through two private equity ownership cycles. In 2011, Alan managed the sale of Standard Steel to Sumitomo Metal Industries and Sumitomo Corporation. Alan began his career in the PricewaterhouseCoopers Pittsburgh audit practice from 1994-1999. He received an Alumni Achievement Award from The Pennsylvania State University in 2007, and in 2006 was awarded “CFO of the Year” by the Pittsburgh Business Times in the large private company category. Alan holds an MBA from The Pennsylvania State University’s Smeal College of Business Administration, and a B.S. in Accounting from Grove City College.
Bill Grubb
Vice President, Business Development and InnovationBill Grubb, Vice President, Business Development and Innovation, oversees all aspects of Noramco’s strategic growth and innovation functions, including acquisitions, partnerships, and new product development platforms. Bill is integral to advancing and diversifying the portfolio of products, developing fast-track processes to move upstream R&D through stage gates, to FDA filings, and to the supply chain. As part of his responsibilities, he also leads the strategic planning, pricing, marketing & external communications functions for Noramco. Joining Noramco in 1997, Bill brings a unique perspective to the role, having spent equal time in development, operations, and commercial leadership positions. Bill led the global team that developed, filed, and launched 10 of the products that make-up the core Noramco product line today, and before his current role, led the global commercial team. He has a 25+ year proven track record of success in the branded drug and generic API industry, working for Burroughs-Welcome, Glaxo, and Johnson & Johnson. Bill holds a degree in Chemistry and Physics and a strategic management certificate from Northwestern’s Kellogg School of Management.
Scott Warner
Vice President & General CounselScott Warner, Vice President & General Counsel, is the Chief legal officer managing the day-to-day legal support for Noramco, responsible for aligning the legal function with strategic business goals. Scott is a solutions oriented business attorney adept at managing risk while facilitating rapid corporate growth. He is an expert in complex legal issues with a proven track record of driving negotiations to the desired outcome, and has deep experience in joint ventures, mergers and acquisitions, compliance and data privacy, insurance, and intellectual property. Prior to joining Noramco, Scott was General Counsel for a private-equity owned CDMO with nearly 1000 employees operating out of seven sites in the US and Europe. Before going in-house, he spent many years in private practice. In 1995, Scott was appointed by President Clinton as one of three U.S. representatives on a four-year joint diplomatic committee, successfully resolving issues for the transfer of control of the Canal from the US to Panama. In November 2013, Scott completed the 140.6 mile Florida Ironman. In addition to his law degree, Scott has an MBA in finance.
Josh Hoerner
Head of Research and DevelopmentJosh Hoerner is the General Manager of Purisys, LLC (a subsidiary of Noramco) and heads all operations for that business unit. Josh also serves as the Head of Noramco R&D. During his tenure at Noramco over the last 9 years, Josh has held a variety of technical and business roles, significantly expanding Noramco’s portfolio and modernizing its key manufacturing technologies. Prior to working at Noramco, Josh served as a Principal Scientist at Merck & Co., where he was responsible for integrated product development and lifecycle management strategy of Boceprevir, Zontivity, and Liptruzet. Josh holds a PhD in Chemistry from the University of Massachusetts Amherst.